Table 9.4.
Median cost of insulin products in the U.S. calculated as AWP (72) and NADAC (73) per 1,000 units of specified dosage form/product
| Insulins | Compounds | Dosage form/product | Median AWP (min, max)* | Median NADAC* |
|---|---|---|---|---|
| Rapid-acting | • Lispro follow-on product | U-100 vial | $118 ($118, $157) | $94 |
| U-100 prefilled pen | $151 | $121 | ||
| • Lispro | U-100 vial | $99† | $79† | |
| U-100 cartridge | $408 | $326 | ||
| U-100 prefilled pen | $127† | $102† | ||
| U-200 prefilled pen | $424 | $339 | ||
| • Lispro-aabc | U-100 vial | $330 | $261 | |
| U-100 prefilled pen | $424 | $339 | ||
| U-200 prefilled pen | $424 | NA | ||
| • Glulisine | U-100 vial | $341 | $272 | |
| U-100 prefilled pen | $439 | $351 | ||
| • Aspart | U-100 vial | $174† | $140† | |
| U-100 cartridge | $215† | $172† | ||
| U-100 prefilled pen | $224† | $180† | ||
| • Aspart (“faster acting product”) | U-100 vial | $347 | $277 | |
| U-100 cartridge | $430 | $344 | ||
| U-100 prefilled pen | $447 | $357 | ||
| • Inhaled insulin | Inhalation cartridges | $1,418 | NA | |
| Short-acting | • Human regular | U-100 vial | $165†† | $132†† |
| U-100 prefilled pen | $208 | $166 | ||
| Intermediate-acting | • Human NPH | U-100 vial | $165†† | $132†† |
| U-100 prefilled pen | $208 | $168 | ||
| Concentrated human regular insulin | • U-500 human regular insulin | U-500 vial | $178 | $142 |
| U-500 prefilled pen | $230 | $184 | ||
| Long-acting | • Glargine follow-on products | U-100 prefilled pen | $261 ($118, $323) | $209 ($209, $258) |
| U-100 vial | $118 ($118, $323) | $95 | ||
| • Glargine | U-100 vial; U-100 prefilled pen | $136† | $109† | |
| U-300 prefilled pen | $346 | $277 | ||
| • Detemir | U-100 vial; U-100 prefilled pen | $370 | $296 | |
| • Degludec | U-100 vial; U-100 prefilled pen; U-200 prefilled pen | $407 | $326 | |
| Premixed insulin products | • NPH/regular 70/30 | U-100 vial | $165†† | $133†† |
| U-100 prefilled pen | $208 | $167 | ||
| • Lispro 50/50 | U-100 vial | $342 | $274 | |
| U-100 prefilled pen | $424 | $339 | ||
| • Lispro 75/25 | U-100 vial | $342 | $273 | |
| U-100 prefilled pen | $127† | $103† | ||
| • Aspart 70/30 | U-100 vial | $180† | $146† | |
| U-100 prefilled pen | $224† | $178† | ||
| Premixed insulin/GLP-1 RA products | • Glargine/Lixisenatide | 100/33 μg prefilled pen | $646 | $517 |
| • Degludec/Liraglutide | 100/3.6 μg prefilled pen | $944 | $760 |
AWP, average wholesale price; GLP-1 RA, glucagon-like peptide 1 receptor agonist; NA, data not available; NADAC, National Average Drug Acquisition Cost.
*
AWP or NADAC calculated as in Table 9.3.
†
Generic prices used when available.
††
AWP and NADAC data presented do not include vials of regular human insulin and NPH available at Walmart for approximately $25/vial; median listed alone when only one product and/or price.